ZA963863B - Recombinant viral vector system. - Google Patents

Recombinant viral vector system.

Info

Publication number
ZA963863B
ZA963863B ZA9603863A ZA963863A ZA963863B ZA 963863 B ZA963863 B ZA 963863B ZA 9603863 A ZA9603863 A ZA 9603863A ZA 963863 A ZA963863 A ZA 963863A ZA 963863 B ZA963863 B ZA 963863B
Authority
ZA
South Africa
Prior art keywords
recombinant viral
viral vector
vector system
recombinant
encapsidation
Prior art date
Application number
ZA9603863A
Other languages
English (en)
Inventor
Richard J Samulski
Xiao Xiao
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of ZA963863B publication Critical patent/ZA963863B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9603863A 1995-05-15 1996-05-15 Recombinant viral vector system. ZA963863B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/440,738 US5869305A (en) 1992-12-04 1995-05-15 Recombinant viral vector system

Publications (1)

Publication Number Publication Date
ZA963863B true ZA963863B (en) 1998-02-20

Family

ID=23749972

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603863A ZA963863B (en) 1995-05-15 1996-05-15 Recombinant viral vector system.

Country Status (10)

Country Link
US (2) US5869305A (de)
EP (1) EP0828519B1 (de)
JP (1) JP4063319B2 (de)
AT (1) ATE411818T1 (de)
AU (1) AU699973B2 (de)
CA (1) CA2221292A1 (de)
DE (1) DE69637723D1 (de)
IL (1) IL118259A0 (de)
WO (1) WO1996036364A1 (de)
ZA (1) ZA963863B (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856585A1 (de) * 1997-01-29 1998-08-05 Introgene B.V. Ein induzierbares Replications- und Expressionssystem
WO1998051810A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US6642051B1 (en) * 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
IT1297074B1 (it) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
US6783972B1 (en) 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
ATE454445T1 (de) * 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20040043488A1 (en) * 1999-02-17 2004-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Adeno-associated viral gene-transfer vector system
US6893865B1 (en) * 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US7893021B2 (en) * 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US6165754A (en) * 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
ES2308989T3 (es) * 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US6544786B1 (en) 1999-10-15 2003-04-08 University Of Pittsburgh Of The Commonwealth Of Higher Education Method and vector for producing and transferring trans-spliced peptides
EP1626091B1 (de) * 2000-06-01 2014-07-23 University Of North Carolina At Chapel Hill Doppelsträngige Parvovirus-Vektoren
DE60117550T2 (de) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
EP1402023A4 (de) * 2001-05-31 2005-06-15 Univ Rockefeller Verfahren zur erzeugung replikationsdefizienter virusvektoren, die helfer-frei sind
US8241622B2 (en) * 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
DK1572169T3 (da) * 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
EP1495123B1 (de) * 2002-03-26 2013-10-30 Zensun (Shanghai) Science and Technology Limited Auf erbb3 beruhende verfahren und zusammensetzungen zur behandlung von neoplasmen
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CA2500397A1 (en) * 2002-09-26 2004-04-08 Greenville Hospital System Aav itr-mediated modulation
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
US7892809B2 (en) * 2004-12-15 2011-02-22 The University Of North Carolina At Chapel Hill Chimeric vectors
US20090191597A1 (en) * 2006-01-20 2009-07-30 Asklepios Biopharmaceutical, Inc. Enhanced production of infectious parvovirus vectors in insect cells
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
US8324149B2 (en) * 2008-11-18 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Encapsidation of heterologous entities into virus-like particles
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
LT3421603T (lt) 2009-05-02 2022-01-10 Genzyme Corporation Genų terapija, skirta neurodegeneraciniams sutrikimams
SG183929A1 (en) 2010-03-29 2012-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
EP2605798A1 (de) 2010-07-12 2013-06-26 Universidad Autònoma de Barcelona Gentherapiezusammensetzung für die behandlung von diabetes
EP3818991A3 (de) 2012-06-19 2021-07-14 University of Florida Research Foundation, Inc. Zusammensetzungen und verfahren zur behandlung von krankheiten
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
BR112016020688B1 (pt) 2014-03-09 2024-01-30 The Trustees Of The University Of Pennsylvania Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
EP3134431B1 (de) 2014-04-25 2021-04-07 The Trustees Of The University Of Pennsylvania Ldlr-varianten und deren verwendung in zusammensetzungen zur verringerung des cholesterinspiegels
SI3142750T1 (sl) 2014-05-13 2020-11-30 The Trustees Of The University Of Pennsylvania Sestavki, ki vsebujejo AAV izražen dvojni protitelesni konstrukt in uporaba le-tega
EP3194430A1 (de) 2014-09-16 2017-07-26 Universitat Autònoma De Barcelona Adeno-assoziierte virusvektoren zur gentheraüie von stoffwechselkrankheiten
CA2974235A1 (en) 2015-01-07 2016-07-14 Universitat Autonoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
WO2016176191A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
US10676735B2 (en) 2015-07-22 2020-06-09 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
KR20180057609A (ko) 2015-08-06 2018-05-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Glp-1 및 대사성 질환 치료용 조성물에서 이의 용도
EP4345454A2 (de) 2015-08-25 2024-04-03 Duke University Zusammensetzungen und verfahren zur verbesserung der spezifität in der genomischen manipulation unter verwendung von rna-geführten endonukleasen
EP3344650A4 (de) 2015-08-31 2019-04-17 The Trustees Of The University Of Pennsylvania Aav-epo zur behandlung von haustieren
CA2999299A1 (en) 2015-09-24 2017-03-30 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
WO2017062750A1 (en) 2015-10-09 2017-04-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating stargardt's disease and other ocular disorders
EP3362571A4 (de) 2015-10-13 2019-07-10 Duke University Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
CA3003435A1 (en) 2015-10-28 2017-05-04 The Trustees Of The University Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
EP3400304B1 (de) 2015-12-11 2022-04-06 The Trustees Of The University Of Pennsylvania Gentherapeutische behandlung der familiären hypercholesterinämie
EP3389724B1 (de) 2015-12-14 2020-07-01 The Trustees Of The University Of Pennsylvania Gentherapie für augenerkrankungen
JP7061067B2 (ja) 2015-12-14 2022-04-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア クリグラー・ナジャー症候群の処置のための組成物
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
MA43735A (fr) 2016-03-07 2018-11-28 Univ Iowa Res Found Expression médiée par aav utilisant un promoteur et un activateur synthétiques
IL297095A (en) 2016-07-08 2022-12-01 Univ Pennsylvania Methods and preparations for the treatment of disorders and diseases involving rdh12
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
ES2931960T3 (es) 2016-12-01 2023-01-05 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de enfermedades degenerativas retinianas
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
WO2018139637A1 (ja) * 2017-01-30 2018-08-02 学校法人日本医科大学 核酸封入aav中空粒子
EP3595688A4 (de) 2017-02-20 2020-12-30 The Trustees Of The University Of Pennsylvania Gentherapie zur behandlung familiärer hypercholesterinämie
KR20190135000A (ko) 2017-02-28 2019-12-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Aav 벡터를 기반으로 하는 인플루엔자 백신
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CN110741082A (zh) 2017-02-28 2020-01-31 宾夕法尼亚州大学信托人 腺相关病毒(aav)进化枝f载体及其用途
CN110582572A (zh) 2017-03-01 2019-12-17 宾夕法尼亚州立大学托管会 用于眼部病症的基因疗法
WO2018200542A1 (en) 2017-04-24 2018-11-01 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
SG10201912401QA (en) 2017-05-11 2020-02-27 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinoses
BR112019024608A2 (pt) 2017-05-24 2020-06-23 Universitat Autonoma De Barcelona Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21)
US11793887B2 (en) 2017-05-31 2023-10-24 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
WO2018232149A1 (en) 2017-06-14 2018-12-20 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
MX2020002501A (es) * 2017-09-08 2020-09-17 Generation Bio Co Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.
US20200297871A1 (en) 2017-09-15 2020-09-24 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
KR20200090927A (ko) 2017-12-19 2020-07-29 아카우오스, 인크. 내이에 대한 치료적 항체의 aav-매개 전달
IT201800004253A1 (it) 2018-04-05 2019-10-05 Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
BR112021006060A2 (pt) 2018-10-01 2021-07-20 The Trustees Of The University Of Pennsylvania composições úteis para tratamento de gangliosidose gm1
WO2020109314A1 (en) 2018-11-26 2020-06-04 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
JP2022523766A (ja) 2019-02-22 2022-04-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Grn関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
AU2020229772A1 (en) 2019-02-26 2021-08-26 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
EP3976087A1 (de) 2019-05-31 2022-04-06 Universitat Autònoma De Barcelona Insulingentherapie
CN114269940A (zh) * 2019-07-03 2022-04-01 学校法人日本医科大学 用于产生包封核酸的aav中空颗粒的方法
EP4007814A1 (de) 2019-07-26 2022-06-08 Akouos, Inc. Verfahren zur behandlung von hörverlust unter verwendung eines sekretierten zielproteins
JP2023505851A (ja) 2019-12-10 2023-02-13 武田薬品工業株式会社 ハンター病治療用のアデノ随伴ウイルスベクター
EP4121168A1 (de) 2020-03-20 2023-01-25 University of Florida Research Foundation, Inc. Gentherapie für das schabyne-syndrom
MX2022014204A (es) 2020-05-13 2023-04-14 Akouos Inc Composiciones y metodos para tratar la perdida auditiva asociada al gen slc26a4.
US20230201306A1 (en) 2020-05-26 2023-06-29 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
BR112023000428A2 (pt) 2020-07-10 2023-03-14 Inst Nat Sante Rech Med Métodos e composições para tratar epilepsia
MX2023002293A (es) 2020-08-24 2023-05-19 Univ Pennsylvania Vectores virales que codifican fusiones de agonistas del receptor de glp-1 y usos de estos en el tratamiento de enfermedades metabólica.
BR112023002904A2 (pt) 2020-08-26 2023-04-25 Univ Pennsylvania Vírus adenoassociado recombinante para tratar neurodegeneração com início na idade adulta associada a grn
IL301643A (en) 2020-10-07 2023-05-01 Regenxbio Inc Gene therapy for ocular manifestations of CLN2 disease
US20230383313A1 (en) 2020-10-18 2023-11-30 The Trustees Of The University Of Pennsylvania Improved adeno-associated virus (aav) vector and uses therefor
WO2022094078A1 (en) 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
CA3196499A1 (en) 2020-10-29 2022-05-05 James M. Wilson Aav capsids and compositions containing same
PE20240115A1 (es) 2020-12-01 2024-01-22 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular
EP4256065A2 (de) 2020-12-01 2023-10-11 The Trustees of The University of Pennsylvania Neue zusammensetzungen mit gewebespezifischen zielmotiven und zusammensetzungen damit
PE20240012A1 (es) 2020-12-29 2024-01-04 Akouos Inc Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1
EP4284440A1 (de) 2021-01-30 2023-12-06 Universitat Autònoma De Barcelona Gentherapie für monogene diabetes
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
TW202302855A (zh) 2021-02-26 2023-01-16 日商武田藥品工業股份有限公司 用於治療法布瑞氏症之組成物及方法
CN113549642B (zh) * 2021-03-02 2023-03-07 体必康生物科技(广东)股份有限公司 一种结核分枝杆菌整合型表达质粒及其应用
IL307633A (en) 2021-04-12 2023-12-01 Univ Pennsylvania Useful preparations in the treatment of spinal muscular atrophy (SBMA)
WO2022226296A2 (en) 2021-04-23 2022-10-27 University Of Rochester Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
EP4089171A1 (de) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Rekombinante tert-codierende virale genome und vektoren
CA3228916A1 (en) 2021-08-11 2023-02-16 King's College London Compositions and methods for improved treatment of disorders affecting the central nervous system
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
AU2022356427A1 (en) 2021-09-30 2024-05-09 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
TW202325845A (zh) 2021-10-02 2023-07-01 賓州大學委員會 新穎aav衣殼及含其之組成物
TW202340467A (zh) 2022-01-10 2023-10-16 賓州大學委員會 有用於治療c9orf72介導之病症之組成物及方法
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
WO2023187728A1 (en) 2022-04-01 2023-10-05 Takeda Pharmaceutical Company Limited Gene therapy for diseases with cns manifestations
WO2023196893A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024042485A1 (en) 2022-08-25 2024-02-29 Takeda Pharmaceutical Company Limited Composition for use in the treatment of fabry disease
WO2024052413A1 (en) 2022-09-07 2024-03-14 Universitat Autònoma De Barcelona Beta-hexosaminidase vectors
WO2024056902A2 (en) 2022-09-16 2024-03-21 Christopher Shaw Compositions and methods for treating neurological diseases
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system

Also Published As

Publication number Publication date
DE69637723D1 (de) 2008-12-04
AU699973B2 (en) 1998-12-17
AU5857796A (en) 1996-11-29
EP0828519B1 (de) 2008-10-22
CA2221292A1 (en) 1996-11-21
EP0828519A4 (de) 2001-11-28
JPH11506318A (ja) 1999-06-08
JP4063319B2 (ja) 2008-03-19
US6057152A (en) 2000-05-02
IL118259A0 (en) 1996-09-12
EP0828519A1 (de) 1998-03-18
ATE411818T1 (de) 2008-11-15
US5869305A (en) 1999-02-09
WO1996036364A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
IL118259A0 (en) Recombinant viral vector system
IL107862A0 (en) Recombinant viral vector system
EP1312679B8 (de) Rekombinante MVA Viren und deren Verwendung
HK1018078A1 (en) Recombinant sendai virus
AU3725697A (en) Infectious papillomavirus pseudoviral particles
GB9618477D0 (en) Gene therapy
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
AUPM710194A0 (en) Virus vector
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
FR2720756B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2158869A1 (fr) Virus recombinants, preparation et utilisation en therapie genique
MY119381A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof